Net sales of Cobenfy, whose success is imperative for Bristol Myers, totaled $27 million in the first quarter, handily ...

Bristol-Myers Squibb is undervalued with a 5%+ dividend yield, robust pipeline, and recession-resistant business. Click here ...

Despite a dip in sales and a recent schizophrenia stumble, the company drew an optimistic outlook for sales for the rest of ...

Research advises patients to regularly review their medication, particularly over-the-counter drugs, as they may interfere ...

"Our strong execution in the first quarter drove continued momentum across our Growth Portfolio and meaningful progress in the pipeline," said Christopher Boerner, Ph.D., board ch ...

Bristol-Myers Squibb Company BMY reported first-quarter 2025 adjusted earnings per share (EPS) of $1.80, which comfortably beat the Zacks Consensus Estimate of $1.51. In the year-ago quarter, BMY ...

Agitation is a symptom in many types of dementia that makes patients distressed, restless, and aggressive. Learn about ...